Holger Lode

In 1999 he became a junior faculty member at Scripps, where he developed a tumor model to study immunotherapeutic approaches in a deadly malignancy in childhood called neuroblastoma.

[3][4] He demonstrated that treatment with immunocytokines, which are antibody-cytokine fusion proteins, is effective in this model and that this approach is synergistic with inhibition of angiogenesis[5] as well as tumor vaccines.

At the same time he was awarded an “Emmy-Noether” Fellowship by the “Deutsche Forschungsgemeinschaft” with focus on immunotherapy approaches in neuroblastoma.

In this time period, he developed novel approaches by means of genetic vaccination to treat malignant disease.

[9] In 2002 he became a member of the SIOPEN group[10] and got involved in the clinical development of a monoclonal antibody directed against ganglioside GD2 (ch14.18/CHO).